NCT05171660 2026-02-17Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal CancerSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityPhase 3 Active not recruiting446 enrolled